Glycosylation
is an accepted strategy to improve the therapeutic
value of peptide and protein drugs. Insulin and its analogues are
life-saving drugs for all type I and 30% of type II diabetic patients.
However, they can readily form fibrils which is a significant problem
especially for their use in insulin pumps. Because of the solubilizing
and hydration effects of sugars, it was thought that glycosylation
of insulin could inhibit fibril formation and lead to a more stable
formulation. Since enzymatic glycosylation results in heterogeneous
products, we developed a novel chemical strategy to produce a homogeneous
glycoinsulin (disialo-glycoinsulin) in excellent yield (∼60%).
It showed a near-native binding affinity for insulin receptors A and
B in vitro and high glucose-lowering effects in vivo, irrespective of the route of administration (s.c. vs i.p.). The glycoinsulin retained insulin-like helical
structure and exhibited improved stability in human serum. Importantly,
our disialo-glycoinsulin analogue does not form fibrils at both high
concentration and temperature. Therefore, it is an excellent candidate
for clinical use in insulin pumps.
Am ild and efficientp alladium-catalyzed synthetic method for the C À Hf unctionalization of N-(quinolin-8-yl)ferrocenecarboxamide has been developed. Va rious aryl iodides containingI ,N O 2 ,C N, COMe,C O 2 Et, and NH functionalities and also alkyl iodidesu nderwent the Pd-catalyzed intermolecular carbon-carbon bond forming reactionw ith ferrocenecarboxamide successfully which led to ad iverse array of bis(aryl/alkyl)ferrocenecarboxamidesi n3 4-92% yields.C ross-coupling of the ferrocenylC À H bond with aryl iodidesc an also be achieved utilizing an economical Ni catalyst. Additionally,s elective monoalkylation of ferrocenecarboxamide was studied using sodium bicarbonatea sb ase and dibenzylphosphoric acid as additive under Pd-catalyzed reaction conditions.S ubsequently,r emoval of the directing group,8 -aminoquinoline,f rom bis(aryl)ferrocenecarboxamides led to bis(aryl)ferrocenesb earing versatilem ethyl ester andc arboxaldehyde functional groups.Scheme 2. Substrate scope with regard to aryl/heteroaryl iodides.U nlesso therwises tated, isolated yields using 10 mol% of Pd(OAc) 2 in toluene are given.
Insulin-like peptide 5 (INSL5), the
natural ligand for the relaxin
family peptide receptor 4 (RXFP4), is a gut hormone that is exclusively
produced by colonic L-cells. We have recently developed an analogue
of INSL5, INSL5-A13, that acts as an RXFP4 agonist in vitro and stimulates colorectal propulsion in wild-type mice but not in
RXFP4-knockout mice. These results suggest that INSL5 may have a physiological
role in the control of colorectal motility. To investigate this possibility,
in this study we designed and developed a novel INSL5 analogue, INSL5-A13NR.
This compound is a potent antagonist, without significant agonist
activity, in two in vitro assays. We report here
for the first time that this novel antagonist peptide blocks agonist-induced
increase in colon motility in mice that express RXFP4. Our data also
show that colorectal propulsion induced by intracolonic administration
of bacterial products (short-chain fatty acids, SCFAs) is antagonized
by INSL5-A13NR. Therefore, INSL5-A13NR is an important research tool
and potential drug lead for the treatment of colon motility disorders,
such as bacterial diarrheas.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.